With FDA input pending, the companies are targeting a Phase 3 trial launch in the first half of 2026
Registered Phase 1 Study ClinicalTrials.gov contains a Phase 1 record registered under NCT02637284
Additional treatment approaches being vigorously pursued include monoclonal antibodies designed to attenuate and block the production and deposition of insoluble amyloid (A) protein fragments resulting from amyloid precursor protein proteolysis
Erwin WM, Las Heras F, Islam D, Fehlings MG, Inman RD: The regenerative capacity of the notochordal cell: tissue constructs generated in vitro under hypoxic conditions
For safe and effective lipo B12 injections administered by a highly experienced plastic surgeon, book a consultation with Dr Tarek Bayazid at his clinic in Dubai
Plus, research shows that a well-balanced and healthy gut microbiota possesses the remarkable ability to naturally eliminate mycotoxins from the host